{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:01:49Z","timestamp":1772578909633,"version":"3.50.1"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:p>OBJECTIVES. Studies of adults have shown that thrice-daily hydrocortisone dosing results in more physiologic cortisol profiles than twice-daily dosing. There are no data on thrice-daily dosing and only limited data on twice-daily dosing in children despite the possible adverse effects of glucocorticoid underreplacement or overreplacement.<\/jats:p><jats:p>METHODS. Using 24-hour cortisol and glucose profiles, along with computerized cognitive testing, our aim was to assess prescribed hydrocortisone regimens in children and adolescents with hypopituitarism.<\/jats:p><jats:p>RESULTS. Twenty patients with adrenocorticotrophic hormone deficiency participated. The hydrocortisone dosing regimen was thrice daily in 9 patients and twice daily in 11 patients (mean total daily dose: 8.3 \u00b1 2.6 and 7.6 \u00b1 2.1 mg\/m2 per day, respectively). Those on twice-daily dosing had more waking hours (between 8:00 am and 8:00 pm) below the reference range than those on thrice-daily dosing (5.5 vs 2.1) and more daytime prolonged hypocortisolemia, defined as plasma cortisol level of &amp;lt;50 nmol\/L for \u22654 hours (64% vs 0%). Morning doses &amp;gt;4 mg\/m2 caused larger postdose peaks than &amp;lt;4 mg\/m2 (151 vs 47 nmol\/L, above the 97.5th percentile). However, there was no difference in the length of time taken to reach nadir below the 2.5th percentile (5.2 vs 4.8 hours). This was true for evening doses of &amp;gt;2.5 mg\/m2 and &amp;lt; 2.5 mg\/m2. No hypoglycemia or hyperglycemia was detected in association with low or high cortisol levels. On predose and postdose cognitive testing (34 paired tests), no significant change in reaction speed was detected (453.3 vs 438.8 milliseconds) or in subgroup analysis of those who had symptoms of lethargy, predose cortisol levels of &amp;lt;50 nmol\/L, or prolonged hypocortisolemia.<\/jats:p><jats:p>CONCLUSIONS. Thrice-daily dosing resulted in less frequent and prolonged hypocortisolemia than twice-daily regimens, but we were unable to relate either regimen to acute clinical end points of glycemia, lethargy, or cognitive function.<\/jats:p>","DOI":"10.1542\/peds.2006-2558","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T00:53:29Z","timestamp":1182214409000},"page":"e164-e171","source":"Crossref","is-referenced-by-count":23,"title":["Prolonged Hypocortisolemia in Hydrocortisone Replacement Regimens in Adrenocorticotrophic Hormone Deficiency"],"prefix":"10.1542","volume":"120","author":[{"given":"Ann M.","family":"Maguire","sequence":"first","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Discipline of Paediatrics and Child Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey R.","family":"Ambler","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Discipline of Paediatrics and Child Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Moore","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"McLean","sequence":"additional","affiliation":[{"name":"Centre for Diabetes and Endocrinology Research, Westmead Hospital, Sydney, New South Wales, Australia"},{"name":"Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina G.","family":"Falleti","sequence":"additional","affiliation":[{"name":"CogState Ltd, Carlton South, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher T.","family":"Cowell","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, New South Wales, Australia"},{"name":"Discipline of Paediatrics and Child Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2007,7,1]]},"reference":[{"key":"2021120902020042100_R1","doi-asserted-by":"crossref","unstructured":"Kenny FM, Preeyasombat C, Migeon CJ. Cortisol production rate: II. Normal infants, children, and adults. Pediatrics.\u20081966;37:34\u201342","DOI":"10.1542\/peds.37.6.960"},{"key":"2021120902020042100_R2","doi-asserted-by":"crossref","unstructured":"Esteban NV, Loughlin T, Yergey AL et al. Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry. J Clin Endocrinol Metab.\u20081991;72:39\u201345","DOI":"10.1210\/jcem-72-1-39"},{"key":"2021120902020042100_R3","doi-asserted-by":"crossref","unstructured":"Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab.\u20081993;76:1505\u20131510","DOI":"10.1210\/jcem.76.6.8501158"},{"key":"2021120902020042100_R4","doi-asserted-by":"crossref","unstructured":"Linder BL, Esteban NV, Yergey AL, Winterer JC, Loriaux DL, Cassorla F. Cortisol production rate in childhood and adolescence. J Pediatr.\u20081990;117:892\u2013896","DOI":"10.1016\/S0022-3476(05)80128-3"},{"key":"2021120902020042100_R5","doi-asserted-by":"crossref","unstructured":"Charmandari E, Johnston A, Brook CG, Hindmarsh PC. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol.\u20082001;169:65\u201370","DOI":"10.1677\/joe.0.1690065"},{"key":"2021120902020042100_R6","doi-asserted-by":"crossref","unstructured":"Derendorf H, Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol.\u20081991;31:473\u2013476","DOI":"10.1002\/j.1552-4604.1991.tb01906.x"},{"key":"2021120902020042100_R7","doi-asserted-by":"crossref","unstructured":"Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet.\u20081992;340:1188\u20131192","DOI":"10.1016\/0140-6736(92)92892-J"},{"key":"2021120902020042100_R8","doi-asserted-by":"crossref","unstructured":"Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf).\u20081997;46:75\u201381","DOI":"10.1046\/j.1365-2265.1997.d01-1749.x"},{"key":"2021120902020042100_R9","doi-asserted-by":"crossref","unstructured":"Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet.\u20081990;336:285\u2013288","DOI":"10.1016\/0140-6736(90)91812-O"},{"key":"2021120902020042100_R10","doi-asserted-by":"crossref","unstructured":"Peacey SR, Guo CY, Robinson AM et al. Glucocorticoid replacement therapy: are patients over treated and does it matter. Clin Endocrinol (Oxf).\u20081997;46:255\u2013261","DOI":"10.1046\/j.1365-2265.1997.780907.x"},{"key":"2021120902020042100_R11","doi-asserted-by":"crossref","unstructured":"al Shoumer KA, Beshyah SA, Niththyananthan R, Johnston DG. Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin Endocrinol (Oxf).\u20081995;42:85\u201390","DOI":"10.1111\/j.1365-2265.1995.tb02602.x"},{"key":"2021120902020042100_R12","doi-asserted-by":"crossref","unstructured":"McConnell EM, Bell PM, Ennis C, et al. Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism. Clin Endocrinol (Oxf).\u20082002;56:195\u2013201","DOI":"10.1046\/j.0300-0664.2001.01447.x"},{"key":"2021120902020042100_R13","doi-asserted-by":"crossref","unstructured":"DeVile CJ, Stanhope R. Hydrocortisone replacement therapy in children and adolescents with hypopituitarism. Clin Endocrinol (Oxf).\u20081997;47:37\u201341","DOI":"10.1046\/j.1365-2265.1997.2101025.x"},{"key":"2021120902020042100_R14","doi-asserted-by":"crossref","unstructured":"Sieratzki JS, Gompels C, Poyser K, Beaman J, Savage DC. Filter paper cortisol profiles in secondary adrenocortical insufficiency. Arch Dis Child.\u20081995;73:351\u2013353","DOI":"10.1136\/adc.73.4.351"},{"key":"2021120902020042100_R15","doi-asserted-by":"crossref","unstructured":"Groves RW, Toms GC, Houghton BJ, Monson JP. Corticosteroid replacement therapy: twice or thrice daily?J R Soc Med.\u20081988;81:514\u2013516","DOI":"10.1177\/014107688808100906"},{"key":"2021120902020042100_R16","doi-asserted-by":"crossref","unstructured":"Mollica CM, Maruff P, Collie A, Vance A. Repeated assessment of cognition in children and the measurement of performance change. Child Neuropsychology.\u20082005;11:303\u2013310","DOI":"10.1080\/092970490911306"},{"key":"2021120902020042100_R17","doi-asserted-by":"crossref","unstructured":"Crown A, Lightman S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf).\u20082005;63:483\u2013492","DOI":"10.1111\/j.1365-2265.2005.02320.x"},{"key":"2021120902020042100_R18","doi-asserted-by":"crossref","unstructured":"Plat L, Leproult R, L'Hermite-Baleriaux M, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab.\u20081999;84:3082\u20133092","DOI":"10.1210\/jc.84.9.3082"},{"key":"2021120902020042100_R19","doi-asserted-by":"crossref","unstructured":"de Lacerda L, Kowarski A, Migeon CJ. Diurnal variation of the metabolic clearance rate of cortisol. Effect on measurement of cortisol production rate. J Clin Endocrinol Metab.\u20081973;36:1043\u20131049","DOI":"10.1210\/jcem-36-6-1043"},{"key":"2021120902020042100_R20","doi-asserted-by":"crossref","unstructured":"Merke DP, Cho D, Anton Calis K, Keil MF, Chrousos GP. Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. J Clin Endocrinol Metab.\u20082001;86:441\u2013445","DOI":"10.1210\/jcem.86.1.7275"},{"key":"2021120902020042100_R21","unstructured":"Ross RJM. Optimization of adrenal glucocorticoid replacement therapy [abstract]. Presented at: annual meeting of the Endocrine Society; June 24\u201327, 2006; Boston, MA"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/e164\/1120220\/zpe0070700e164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/e164\/1120220\/zpe0070700e164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T11:57:54Z","timestamp":1683892674000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/120\/1\/e164\/70620\/Prolonged-Hypocortisolemia-in-Hydrocortisone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,7,1]]},"published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-2558","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}